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Monocytes are mononuclear cells characterized by distinct morphology and expression of CD14 and CD16 surface receptors.
Classical, quiescent monocytes are positive for CD14 (lipopolysaccharide receptor) but do not express Fc gamma receptor III
(CD16). Intermediatemonocytes coexpress CD16 andCD14.Nonclassicalmonocytes with low expression of CD14 representmature
macrophage-like monocytes. Monocyte behavior in peripheral arterial disease (PAD) and during vessel wall directed treatment is
not well defined. This observation study aimed at monitoring of acute changes in monocyte subpopulations during percutaneous
transluminal angioplasty (PTA) in PAD patients. Patients with Rutherford 3 and 4 PAD with no signs of inflammatory process
underwent PTA of iliac, femoral, or popliteal segments. Flow cytometry for CD14, CD16, HLA-DR, CD11b, CD11c, and CD45RA
antigens allowed characterization of monocyte subpopulations in blood sampled before and after PTA (direct angioplasty catheter
sampling). Patients were clinically followed up for 12 months. All 61 enrolled patients completed 12-month follow-up. Target vessel
failure occurred in 12 patients. While absolute counts of monocyte were significantly lower after PTA, only subtle monocyte
activation after PTA (CD45RA and 𝛽-integrins) occurred. None of the monocyte parameters correlated with long-term adverse
clinical outcome. Changes in absolute monocyte counts and subtle changes towards an activation phenotype after PTAmay reflect
local cell adhesion phenomenon in patients with Rutherford 3 or 4 peripheral arterial disease.
1. Introduction
Monocytes account for 3% to 8% of peripheral blood leuko-
cytes. They are mononuclear cells characterized by specific
morphology but more accurately by their expression of
CD14 and CD16 surface receptors [1]. They represent the
main component of the innate immunity, and their default
mode of action is phagocytosis. However, they are also
involved in endogenous inflammatory processes including
atherosclerotic plaque formation.Monocytes promote leuko-
cyte recruitment to plaques and activate inflammatory signal-
ing pathways, such as nuclear factor kappa-B. Monocytes [2]
and cholesterol-loaded macrophages are a characteristic his-
tology finding of atherosclerotic plaque and seem to bemajor
players in all stages of atherosclerotic plaque development.
This process starts with monocyte adhesion to endothelial
cells mediated by selectins and integrin ligands. Subsequent
rolling of monocytes on activated endothelial cells is depen-
dent on the interaction of E-selectin with monocytic P-
selectin glycoprotein ligand-1 (PSGL-1) [3]. Firm attachment
between cells is possible as a result of interaction between
endothelial integrin ligands, such as VCAM-1 (vascular cell
adhesion molecule-1) and ICAM-1 (intercellular adhesion
molecule-1) and monocytic VLA-4 (very late antigen-4) or
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Table 1: Differential expression patterns of crucial markers of key
monocyte subsets [11].
Subset Markers
CD14++CD16− (classical) CCR2, FcgRI, CD62L, PSGL-1,IL-6R, SR-A, CD36
CD14++CD16+ (intermediate) CCR5, CD163, TLR4, HLA-DR,CD105, Tie2, VEGFR1/2
CD14+CD16++ (nonclassical) CX3CR1, CD49d, sialophorin,SLAN
LFA-1 (lymphocyte function-associated antigen 1) andMAC-
1 (macrophage-1 antigen) [4]. After adhesion, monocytes
migrate to the intimal layer of vascular wall, the process that
is PECAM-1 (platelet-endothelial cell adhesion molecule-1,
CD31) and CD99 dependent [5].
The extent of the inflammatory infiltrates and their strate-
gic location within the protective fibrous cap is associated
with plaque rupture and thrombosis [6]. Adventitial inflam-
mation has also been described and is linked with an expan-
sion of the adventitial vasa vasorum in unstable atherosclero-
sis [7]. Macrophage differentiation frommonocytes is critical
phenomenon for the development of atherosclerosis [8].
Macrophages are heterogeneous cells, and when they are
appropriately activated, they phagocytose cytotoxic lipopro-
teins, clear apoptotic bodies, secrete anti-inflammatory
cytokines, and synthesize matrix repair proteins that stabilize
vulnerable plaques [9]. Morphology studies show the his-
tological similarity of atherosclerotic plaque initiation and
development independent of actual lesion location [10].
Three key populations of monocytes in humans were
characterized (see Table 1).
Classical, quiescent monocytes are positive for CD14
(lipopolysaccharide (LPS) receptor) but do not express Fc
gamma receptor III (CD16). CD16+ monocytes coexpressing
CD14 possess proinflammatory and proatherogenic prop-
erties, although their nature varies depending on the level
of CD14 expression. Nonclassical cells with low expres-
sion of CD14, that is, CD14+CD16++, represent a mature
macrophage-like monocyte, being an important source of
tumor necrosis factor-alpha (TNF-alpha), while the role of
intermediate CD14++CD16+ monocytes is less clear. Both
intermediate and nonclassical monocyte populations are
linked to the pathogenesis of the cardiovascular disease [12,
13] and with myocardial dysfunction and recovery following
myocardial infarction, although their relationship to subclin-
ical atherosclerosis is less clearly defined [14].
Both clinical and experimental studies suggest that clas-
sical and intermediate populations play a role in poor short-
term and intermediate-term cardiovascular outcomes.
Still, monocyte biology in atherogenesis is poorly under-
stood, and puzzling findings remain. No coherent associ-
ation between monocyte counts and cardiovascular (CV)
disease was observed in large epidemiological studies [15,
16]. CD14++CD16+ monocytes independently predicted car-
diovascular events in subjects referred for elective coronary
angiography [17]. Also, CD14++CD16+ monocytes but not
total monocyte numbers were independently associated with
CV events in both nondialysis [18] and dialyzed [13] chronic
kidney disease patients.
Peripheral arterial disease (PAD) is a vascular disorder
of atherosclerotic origin [10]. Lower extremity peripheral
artery disease is the third leading cause of atherosclerotic
cardiovascular morbidity, following coronary artery disease
and stroke. PAD is a global disease with exponential growth
also in developing countries [19]. By 2020, cardiovascular
diseases are predicted to be themajor causes ofmorbidity and
mortality in most developing nations around the world [20].
It is not clear whether endovascular treatment of PAD
allows for postponing and avoiding deleterious effects of
peripheral ischemia such as critical limb ischemia (CLI) and
major amputation. Patients with CLI are at particular risk of
major cardiac and cerebrovascular events and over 20% of
them die within a year after CLI diagnosis [21].
Previous studies reported the correlation of systemic
inflammatory status and progression of peripheral arte-
rial disease (PAD) [22]. Several inflammatory biomarkers,
including high sensitivity C-reactive protein (CRP) [23],
soluble adhesion molecules (such as sICAM [24]), and
tumor necrosis factor-𝛼 (TNF-𝛼) [25], are associated with
both the incidence and severity of PAD [26]. Inflammation
increases the risk of adverse graft outcomes in PAD patients
who have undergone peripheral bypass surgery [27], and
greater systemic inflammation is associated with increased
cardiovascular morbidity and mortality in individuals with
PAD [28]. Monocytes were the only WBC type significantly
and independently associated with PAD in a representative
sample of the US population after adjustment for other
inflammatory markers [29]. Additionally, monocytes from
PAD patients were shown to form aggregates with platelets in
vivo [30] and adhere easier to cultured endothelial cells [31].
Endovascular treatment of PAD allowed controlling
symptomatic disease in many cases. It is minimally invasive
and is still a very efficient way to combat arterial stenosis
and occlusion. Acute changes in circulating cell populations
were demonstrated in course of endovascular treatment [32].
Moreover, endovascular procedure is a unique opportunity to
access and evaluate direct vicinity of atherosclerotic plaque in
vivo.
Both plaque contents and subendothelial space are
exposed during percutaneous transluminal angioplasty
(PTA). It was recently demonstrated [33] that subendothelial
resistin activated smoothmuscle cells (SMC) by upregulating
fractalkine, MCP-1 expression, and monocyte chemotaxis.
Except for activation of Toll-like receptor 4 (TLR4) and Gi/o
proteins, both fractalkine and MCP-1 enhanced recruitment
of monocytes to subendothelial space involving CX3CR1 and
CCR2 receptors.
Therefore, we hypothesized that acute changes in mono-
cyte subpopulations may occur during PTA. And this
study aimed at evaluation of monocyte subpopulations in
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PAD patients during the peripheral transluminal angioplasty
(PTA) procedure.
2. Materials and Methods
2.1. Setting. Patients were recruited at the tertiary angiology
center at the university hospital and the largest provider of
peripheral arterial endovascular therapy in the Malopolska
region of Poland, serving a population of approximately
3.3 million inhabitants. The treatment details of patients
admitted to the department were entered prospectively into
a specific database called the Malopolska Endovascular Reg-
istry [34, 35].
2.2. Patients. Patients with PAD who required endovascular
treatment for severe claudication or rest pain and met all
inclusion criteria entered the study group.
Patients with any signs of inflammation, ischemic and
trophic ulcerations, chronic kidney disease, neoplastic dis-
ease, or elevated CRP were excluded. Body temperature was
measured on the day preceding procedure and immediately
before the procedure. They were consequently evaluated
for symptoms and signs of peripheral ischemia (including
baseline Rutherford’s scale classification and ankle-brachial
index (ABI)). Preprocedural imaging studies (ultrasound
color Doppler or CT angiography) helped in the proper
planning of endovascular treatment. PTA was performed in
iliac, femoral, or popliteal vascular segments.
Thus, the group studied corresponded to stage 3 or
stage 4 of PAD using Rutherford’s classification. All subjects
in this study received an identical treament consisting of
antiplatelet aspirin (75mg) as well as atorvastatin (20–40mg)
and clopidogrel (75mg). All patients signed an informed
consent form and the local Jagiellonian University Ethical
Committee accepted this study (KBET/282/B/2013). Due to
the observational character, the study was not submitted to
the public trial database.
2.3. Procedure and Blood Sampling. Vascular access was
achieved in all cases by common femoral artery puncture
and 6F arterial introducer. After assuring arterial access, a
diagnostic angiography of target vessel was performed with
administration of ca. 30mL of Ultravist 370 contrast medium
(Ultravist (iopromide) Injection contrast medium, Bayer,
Germany). Bolus injection of 5000 IU of unfractionated
heparinwas given after diagnostic angiography in all patients.
Attention was paid to avoid any modifications of preparation
or treatment protocol to minimize confounders.
Sample 0 was collected after diagnostic angiography
directly from the balloon catheter. Balloon catheters were
sized to reference vessel diameter with quantitative angiog-
raphy. Sample 1 was collected from balloon catheter at
the level of balloon deflation (direct vicinity of the target
atherosclerotic plaque) immediately after balloon deflation
(lasting 30 to 60 seconds). The time between two samplings
did not exceed 15 minutes. Blood (10mL) was sampled to
ethylenediaminetetraacetic acid- (EDTA-) containing vials,
immediately placed on ice, transferred to the laboratory
within 45 minutes, and analyzed.
2.4. Patients’ Follow-Up. All patients were monitored for
clinical results until month 12. Symptomatic follow-up, ABI
measurement, and ultrasound were used to verify vessel
reocclusion.
2.5. Flow Cytometry Analysis of Antigen Expression on Periph-
eral Blood Monocytes. Surface antigens were studied in
peripheral blood mononuclear cells (PBMCs) as previously
described [36]. Briefly, PBMCs were isolated by gradient
centrifugation using Pancoll human (PAN-Biotech GmbH,
Aidenbach, Germany) from the ethylenediaminetetraacetic
acid- (EDTA-) treated blood. PBMCswere further suspended
in phosphate-buffered saline (PBS) containing 1% heat-
inactivated fetal bovine serum (FBS) (Gibco, Life Tech-
nologies, USA) and were used immediately after isolation.
A total of 500,000 PBMCs were stained for 20 minutes
with fluorochrome-conjugated monoclonal antibodies: anti-
CD14-APC-H7 (clone MΦP9), anti-CD16-PE (clone 3G8),
anti-human leukocyte antigen (HLA)-DR-PE-Cy7 (L243),
anti-CD11b/Mac-1-Pacific Blue (clone ICRF44), anti-CD11c-
APC (clone B-LY6), and anti-CD45RA-FITC (clone L48)
(BD, Pharmingen, CA, USA). After staining, cells were
washed twice with PBS containing 1% FBS. Cells were
processed in the FACS Verse flow cytometer and analyzed
using FlowJo software (Tree Star, USA). Monocytes were
gated according to forward scatter (FSC) and side scatter
(SSC) signals as described previously. Subsequently, cellswere
gated in anHLA-DR/CD14 plot to excludeHLA-DR-negative
Natural Killer cells. Finally, we analyzed cells for CD14 and
CD16 expression, which allowed for discrimination of major
monocyte subpopulations: CD14++CD16−, CD14++CD16+,
and CD14+CD16++.
2.6. Statistics. Datawere described usingmeanwith standard
deviations or median with the first and third quartiles for
continuous variables and as counts and percentages for nomi-
nal variables. Continuous variables were compared using Stu-
dents 𝑡-test with or without correction for unequal variances
(verified using Levene’s test) orMann–Whitney𝑈 test for not
normally distributed data (verified using Shapiro-Wilk test).
Data before and after the intervention were compared using
paired version of tests above. Relative and absolute changes
were also analyzed. Nominal variables were compared using
Pearson’s 𝜒2 test or Fisher’s exact test when appropriate.
Logistic regression and Cox’s proportional-hazards models
were calculated to analyze the relationship of total monocyte
and monocyte subset cell counts with event-free survival
after adjustment for age and sex to determine independent
predictors of reintervention.
Data management, statistical analysis, and statistical dis-
covery were performed using JMP, version 12., SAS Institute
Inc., Cary, NC, 1989–2012, and the software environment
for statistical computing, R. Two-sided 𝑝 values < 0.05 were
considered significant.
3. Results
A group of 61 patients with PAD who required PTA were
enrolled in the study. It was a small group but reflected a usual
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Table 2: Demographic and clinical data of 61 patients undergoing
monocyte population sampling and evaluation.
Variable 𝑛 (%) or value
Age (mean ± SD; median) 62.2 ± 10.8; 61 years
Male gender 50 (82%)
Hypertension 33 (54%)
Diabetes
Type 2 16 (26%)
Ischemic heart disease 25 (41%)
Impaired renal function (GFR <
70mL/min/1.73m2) 0 (0%)
Dialysis dependence 0 (0%)
Smoking
Prior 40 (66%)
Current 16 (26%)
Hyperlipidaemia 30 (49%)
Congestive heart failure 0 (0%)
Rutherford-Becker class
3 50 (82%)
4 11 (18%)
Reocclusion within 6-month observation
period 12 (20%)
profile of patients with a high burden of cardiovascular risk.
General patient characteristics are given in Table 2.
Patients were scheduled to receive endovascular treat-
ment in either the iliac, femoral, or popliteal arteries at
our department. The key clinical criterion for inclusion was
severe claudication or resting pain. Ischemia was evaluated
by Rutherford’s scale, ankle-brachial index (ABI), and exam-
ination of arteries using USG with color Doppler or CT
angiography. Ischemic symptoms evaluated by Rutherford’s
scale equaled 3 in 50 subjects and 4 in 11 others. In 21 cases
(34.4%), only PTA was performed, whereas 40 cases (65.6%)
required PTA with stent implantation. However, samples
were taken exclusively before and after angioplasty. No
previous revascularizationwas performed in the target vessel.
No signs of the inflammation were present in all cases at the
time of PTA procedure. Body temperature was below 37∘C,
and peripheral blood leukocytes were within reference range.
During 12-month observation period, 12 cases of clinical
and/or imaging target vessel failure were observed. No
patients were lost to follow-up. There were no cases of
major cardiac and cerebrovascular events such as cardiovas-
cular death, acute myocardial infarction, or nonhemorrhagic
stroke in the studied group during the observation period.
Absolute amounts ofmonocytes isolated before PTAwere
higher than those after PTA (621±159 cells/mm3 versus 556±
146 cells/mm3, 𝑝 = 0.028, Sample 0 versus Sample 1, resp.).
However, no significant differences were observed between
the relative numbers of isolated PBMCs before and after PTA.
Flow cytometry analysis was performed, and representa-
tive pictures are presented in Figures 1 and 2.
No differences were found in monocyte subpopulations
before and after PTA (Table 3).
Significant but subtle changes were observed in mean
fluorescence of CD11b both in total monocyte population
(997±362 versus 1071±383,𝑝 = 0.04) and in CD14++CD16−
(1029 ± 387 versus 1113 ± 419, 𝑝 = 0.04) and CD14++CD16+
(1255 ± 458 versus 1323 ± 461, 𝑝 = 0.045) subsets before and
after PTA.
Also, mean fluorescence of CD11c (703±209 versus 775±
260,𝑝 = 0.03) andCD45RA (1779±412 versus 1808±414,𝑝 =
0.03) in CD14++CD16− population was significantly higher
after PTA.
Attempts were made to compare and find independent
predictors of worse treatment outcome (target vessel failure
at 12 months). However, none of the investigated monocyte-
related markers was significant in this respect, also after
adjustment for age and gender. It concerned both absolute
values of pre-PTA and post-PTA samples and differences
between them.
No systematic difference was noted between patients with
Rutherford classes 3 and 4. Also, stent implantation was not
a significant confounder in this clinical setting.
4. Discussion
PAD is considered as a strong risk factor for the premature
development of atherosclerosis and cardiovascular events.
The mechanisms of this increased risk remain unclear,
although there were some previous reports linking immune
mechanisms and monocyte participation particularly in this
process.
Leukocyte activation was also suggested to be one of the
major factors of detrimental short-term and mid-term treat-
ment results after coronary angioplasty [37, 38]. Additionally,
monocyte chemoattractant protein-1 (MCP-1) was clearly
linked to adverse outcomes of endovascular treatment both
in coronary circulation and in peripheral circulation [39].
We have observed reduction in total monocyte count
during PTA and subtle changes towards activation pattern
in monocyte subpopulations. They did not correlate with
target vessel failure in long-term follow-up.This is essentially
matching recent findings of DeSart et al. [40]. They demon-
strated that endovascular revascularization had only modest
influence on the overall activation state of the systemic
inflammatory system, with baseline variability exceeding
the perturbations induced by the intervention. Conversely,
changes in the monocyte genome are evident during 28 days,
promoting leukocyte extravasation. Additionally, no single
plasma protein predictor correlated with outcome, but a
pattern of genes regulating cell-cycle signaling showing up
after the endovascular procedure was predictive of clinical
outcome.
CD45RA is considered as a marker of activation of
peripheral bloodmonocytes [41] and activation ofmonocytes
in vitro induces their CD45RA expression [42].
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Figure 1: Flow cytometric analysis of monocytes and their subsets from PBMC. Monocytes with a part of lymphocytes (b) were gated
according to forward scatter (FSC) and side scatter (SSC) from peripheral blood mononuclear cells (PBMCs (a)). Subsequently, cells were
gated in an HLA-DR/CD14 plot to exclude HLA-DR-negative Natural Killer cells (c). Finally, monocyte subpopulations were identified
according to CD14 and CD16 expressions (CD14++CD16−, CD14++CD16+, and CD14+CD16++ (d)). Percentages of major monocyte
subpopulations are indicated (d) in Sample 0 (before PTA) and Sample 1 (after PTA).
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Table 3: Characteristics of monocyte subsets defined by expression of CD14 and CD16 in samples from PAD patients before and after PTA.
CD14++CD16− (classical) % CD14++CD16+ (intermediate) % CD14+CD16++ (nonclassical) %
Before PTA (Sample 0) 76.9 ± 7.9 10.2 ± 3.7 10.5 ± 4.9
After PTA (Sample 1) 77.7 ± 7.9 9.9 ± 4.3 10.0 ± 4.6
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Figure 2: Examples of antigen expression on peripheral bloodmonocytes. Surface antigen expressions of CD11b, CD11c, CD45RA, and HLA-
DR were studied on peripheral blood monocytes using flow cytometry. Black histograms indicated antigen expression on cells isolated from
the sample before PTA. Red histogram indicated antigen expression after PTA.
The 𝛽-integrins (CD11b/CD18, CD11c/CD18) expressed
onperipheral bloodmonocytes can interactwith their ligands
including intercellular adhesion molecule-1 (ICAM-1) and
vascular cell adhesion molecule-1 (VCAM-1) on activated
endothelium [43, 44].
An approach to evaluate blood sampled locally from the
vicinity of recently treated atherosclerotic plaque does not
seem to be substantiated at least in acute results of angioplasty
on the expression pattern of surface markers of monocyte
subsets. Lower total amounts of monocytes after PTA suggest
that they are not released from atherosclerotic plaque, but
they may adhere to the vessel wall denuded of endothelium
during the angioplasty treatment.
Subtle differences in CD45RA, CD11b, and CD11c expres-
sions were particularly seen in selected monocyte subsets.
This may reflect migration of cells into the subendothelial
space, adhesion of cells in sites of endothelial injury, or release
of cytokines, resulting in acute subpopulation shift.
The study also had some inherent limitations.The natural
follow-up period was 12 months, and it was treatment related
and not event related, as in previous studies. Although a pos-
sible influence of heparin or contrast media administration
for surface expression of antigens exists, all patients received
identical treatment in order to minimize this possible bias.
There was no external disease-free control group. How-
ever, previous reports exist on the differences in peripheral
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monocyte population between healthy subjects, claudicants,
and critical limb ischemia patients [45]. In this study, we were
interested in acute changes inmonocyte population during an
endovascular treatment.
While it would be very valuable to evaluate other mono-
cyte activation methods such as concentration of activation-
specific human anti-alphaMbeta2 single-chain antibodies
[46] or expression and release of chemokines by transcrip-
tome and chemokinome profiling [47], we were not able to
perform monocyte-specific stimulation studies at the same
time due to grant limitations.
It was an observational cohort study and no causality
could be determined, but further investigation of possible
mechanisms is continued and seems mandated.
5. Conclusion
Peripheral percutaneous transluminal angioplasty induced
reduction in total monocyte count in samples from direct
vicinity of target lesion. No significant acute changes in the
composition of monocyte subpopulation in patients with
Rutherford 3 or 4 peripheral arterial disease were noted,
except for subtle shift towards an activation pattern (CD45RA
and 𝛽-integrins, CD11b and CD11c). A sampling of leuko-
cytes from angioplasty catheter (i.e., the vicinity of target
atherosclerotic plaque) provides additional insight into the
local environment of nonspecific immunological response
even in acute observation.
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